Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Stock Information for Revive Therapeutics Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revive Therapeutics Ltd

Enveric Biosciences Participating in BIO-Europe Spring®
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
Enveric Biosciences CEO Issues Letter to Shareholders
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Enveric Biosciences Announces Closing of $5 Million Public Offering
Enveric Biosciences Announces Pricing of $5 Million Public Offering
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.